Mercado mundial de tratamiento de arritmias: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de tratamiento de arritmias

Se sabe que el tratamiento de las arritmias inhibe la expresión de ciertos genes, algo que es diferente de lo que ocurre con la medicina convencional. En los últimos años, se han desarrollado nuevos oligonucleótidos innovadores capaces de actuar sobre genes específicos y tratar enfermedades crónicas.

Data Bridge Market Research analiza que el mercado de tratamiento de arritmias, que fue de USD 7.64 mil millones en 2022, se espera que alcance los USD 11.06 mil millones para 2030 y se espera que experimente una CAGR del 7,67% durante el período de pronóstico. Esto indica que el valor de mercado. La "cirugía" domina el segmento de tratamiento del mercado de tratamiento de arritmias debido a un aumento en el número de cirugías para arritmias. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento de arritmias

Market Definition

Arrhythmia refers to a type of cardiovascular disorder that is characterized by abnormal heart rhythm. The condition causes irregular heart rate, sometimes slow or too fast, or it may be so brief that it doesn’t change an individual’s heart rate and could lead to more serious heart problem. The disease can have almost no symptoms but patient tends to feel fluttering in the chest or neck.

Global Arrhythmia Treatment Market Dynamics

Drivers

• Increasing Prevalence of Arrhythmia

One of the primary drivers is the rising prevalence of arrhythmia, including atrial fibrillation (AFib) and ventricular tachycardia (VT). The aging population, lifestyle factors, and underlying heart conditions contribute to the growing incidence of arrhythmia worldwide. This higher prevalence creates a larger patient pool in need of treatment

• Technological Advancements in Cardiac Care

Advances in medical technology have led to the development of more sophisticated diagnostic tools and treatment options for arrhythmia. Innovations such as catheter ablation techniques, implantable cardioverter-defibrillators (ICDs), and cardiac rhythm management devices have improved the effectiveness and safety of arrhythmia treatment

• Increasing Awareness and Diagnosis 

Growing awareness of arrhythmia among both patients and healthcare professionals has led to early diagnosis and intervention. Routine cardiac screenings, improved diagnostic accuracy, and regular monitoring have contributed to the early identification of arrhythmia cases, promoting timely treatment and management

• Aging Population and Chronic Disease Burden

The aging global population is at a higher risk of developing arrhythmias, as age is a significant risk factor. In addition, the rising prevalence of chronic conditions such as hypertension, diabetes, and obesity contributes to the development of arrhythmia. As the world's population continues to age and chronic diseases become more common, the demand for arrhythmia treatment is expected to increase

Opportunities

• Telemedicine and Remote Monitoring

The adoption of telemedicine and remote monitoring technologies has surged, offering an opportunity to improve arrhythmia patient care. Remote monitoring devices, such as implantable cardiac monitors (ICMs) and wearables, enable continuous tracking of heart rhythms. Healthcare providers can remotely monitor patients, detect arrhythmia episodes early, and intervene when necessary, leading to better disease management and reduced hospitalizations

• Personalized Medicines and Precision Therapeutics

Advances in genomics and biomarker research provide opportunities for personalized treatment approaches. Tailoring arrhythmia therapies based on a patient's genetic makeup and specific arrhythmia type can enhance treatment effectiveness and reduce adverse effects. Targeted therapies and pharmacogenomic approaches are expected to gain prominence

Restraints/Challenges

• High Treatment Costs

The cost of arrhythmia treatment can be substantial, particularly for advanced therapies such as catheter ablation, implantable devices, and surgical interventions. High treatment costs can limit access to care for some patients, especially in regions with limited healthcare resources or where health insurance coverage is inadequate

• Stringent Regulatory Approvals

Regulatory approval processes for arrhythmia treatment devices and drugs are rigorous and time-consuming. The need to demonstrate safety and efficacy through extensive clinical trials and adhere to complex regulatory requirements can delay product launches and increase development costs. This can hinder the entry of new treatments into the market

• Complexity of Arrhythmia Diagnosis and Treatment

Arrhythmias encompass a wide range of heart rhythm disorders, each with its unique characteristics and treatment requirements. Accurate diagnosis and treatment selection can be challenging due to the complexity of arrhythmia types and the need for specialized equipment and expertise. Healthcare providers may face difficulties in differentiating between various arrhythmias and choosing the most suitable treatment approach

• Shortage of Specialized Healthcare Providers

The management of arrhythmias often requires the expertise of cardiologists, electrophysiologists, and other specialized healthcare professionals. However, there is a shortage of these specialists in many regions, leading to longer wait times for appointments and delayed treatment. Expanding the workforce of arrhythmia specialists is crucial to meet the growing demand for care

This arrhythmia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the arrhythmia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

• In November 2021, Philips agreed to acquire Cardiologs, a France-based medical technology company focused on cardiac diagnostics using AI and cloud technology. The acquisition will strengthen Philips’ cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis, and reporting services
• In May 2021, iRhythm Technologies Inc., a leading digital healthcare solutions company focused on the advancement of cardiac care, received two new 510(k) clearances, one for a new and improved design of its flagship monitor, "new Zio monitor", and a second for updated AI capabilities

Global Arrhythmia Treatment Market Scope

The arrhythmia treatment market is segmented on the basis of type, drugs, devices, treatment, mode of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Supraventricular Arrhythmias
• Ventricular Arrhythmias
• Others

Drugs

• Antiarrhythmic Drugs
• Calcium Channel Blockers
• Beta Blockers
• Anticoagulants Agents
• Others

Devices

• Implantable Cardioverter-Defibrillator (ICD)
• Pacemaker
• Cardiac Resynchronization Therapy (CRT)
• Others

Treatment

• Surgery
• Drugs
• Others

Mode of Administration

• Injectable
• Oral
• Others.

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End-User

• Hospitals
• Homecare
• Specialty Clinics
• Others.

Arrhythmia treatment Market Regional Analysis/Insights

The arrhythmia treatment market is analysed and market size insights and trends are provided by type, drugs, devices, treatment, mode of administration, distribution channel, and end-user as referenced above.

Los países cubiertos en el informe del mercado de tratamiento de arritmias son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de Sudamérica como parte de Sudamérica.

América del Norte domina el mercado de tratamiento de arritmias debido al aumento de las inversiones en actividades de investigación y desarrollo de dispositivos de monitoreo y tratamientos dentro de la región.

Se espera que Asia-Pacífico sea testigo de un alto crecimiento durante el período de pronóstico de 2023 a 2030 debido a la introducción de tecnologías que incluyen dispositivos portátiles y terapias en la región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de caso son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado de tratamiento de arritmias

El panorama competitivo del mercado de tratamiento de arritmias proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de arritmias.

Algunos de los principales actores que operan en el mercado del tratamiento de la arritmia son:

• Pfizer Inc. (Estados Unidos)
• Sawai Pharmaceutical Co., Ltd (Japón)
• Baxter (Estados Unidos)
• Aurobindo Pharma (India)
• Zydus Cadila (India)
• WOCKHARDT (India)
• Industrias farmacéuticas Teva Ltd (Israel)
• Novartis AG (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Sun Ltd (India)
• Fresenius Kabi AG (Alemania)
• GlaxoSmithKline plc (Reino Unido)
• Arbor Pharmaceuticals (Estados Unidos)
• ANI Pharmaceuticals, Inc. (Estados Unidos)
• Vintage Labs (Estados Unidos)
• Nexus Pharmaceuticals, Inc. (Estados Unidos)
• AstraZeneca (Reino Unido)
• Laboratorios Dr. Reddy Ltd (India)
• Acesion Pharma (Dinamarca)
• Johnson & Johnson Services, Inc. (Estados Unidos)
• InCarda Therapeutics, Inc. (EE. UU.),  

SKU-46444